Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DCL001088

Drug Information
NameGDC0941
SynonymsGD9; 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine; EC-000.2335; 4-(2-(1H-Indazol-4-yl)-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)thieno[3,2-d]pyrimidin-4-yl)morpholine; GDC-0941, GDC0941; GDC-0941; nchembio.293-comp12; C53216200; Kinome_3719; GDC 0941; GDC0941; CHEMBL521851; S1065_Selleck
CompanyGenentech
IndicationAdvanced solid tumours; non-Hodgkin¡¯s lymphoma
[ICD9: 140-199, 200, 202, 202.8, 210-229   ICD10: C00-C75, C7A, C7B, C81-C96, C82-C85, D10-D36, D3A]
Phase I    
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C23H27N7O3S2/c1-35(31,32)30-7-5-28(6-8-30)15-16-13-20-21(34-16
)23(29-9-11-33-12-10-29)26-22(25-20)17-3-2-4-19-18(17)14-24-27-19
/h2-4,13-14H,5-12,15H2,1H3,(H,24,27)
InChIKeyLHNIIDJUOCFXAP-UHFFFAOYSA-N
Canonical SMILESCS(=O)(=O)N1CCN(CC1)CC2=CC3=C(S2)C(=NC(=N3)C4=C5C=NNC5=CC=C4)N6CCOCC6    
PubChem Compound IDCID 17755052.
PubChem Substance IDSID 29212926.
ClinicalTrials.govNCT00876122;
TargetPI3KInhibitor[1][2]
Ref 1Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44. To Reference
Ref 2The PI3K/Akt pathway as a target in the treatment of hematologic malignancies. Anticancer Agents Med Chem. 2009 Jun;9(5):550-9. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543